ARST1321: Pazopanib Neoadjuvunt Trial on Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)

Protocol: 
AAAO4053
Phase: 
II/III

ARST1321: Pazopanib Neoadjuvunt Trial on Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)

This randomized phase II/III trial studies how well pazopanib hydrochloride,
combination chemotherapy, and radiation therapy work and compares it to
radiation therapy alone or in combination with pazopanib hydrochloride or
combination chemotherapy in treating patients with newly diagnosed non-
rhabdomyosarcoma soft tissue sarcomas that can be removed by surgery.
Radiation therapy uses high energy x-rays to kill tumor cells. Drugs used in
chemotherapy, such as ifosfamide and doxorubicin hydrochloride, work in
different ways to stop the growth of tumor cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading.
Pazopanib hydrochloride may stop the growth of tumor cells by blocking some
of the enzymes needed for cell growth. It is not yet known whether radiation
therapy works better when given with or without combination chemotherapy
and/or pazopanib hydrochloride in treating patients with non-rhabdomyosarcoma
soft tissue sarcomas.

Are you Eligible? (Inclusion Criteria)

-Subjects must be at least 2 years and up at the time of study entry.
-Patients must have newly diagnosed non-rhabdomyosarcoma soft tissue sarcoma.
-Patients must also meet all eligibility criteria as outlined in the study
protocol.

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States